A newly developed long-term prediction model demonstrated greater accuracy in estimating prostate cancer–specific mortality compared with existing risk assessment tools. Unlike traditional ...
Men with prostate cancer stage cT1c-T2bN0M0, Gleason Score (GS) 2-6 and prostate-specific antigen (PSA) 10-20 or GS 7, and PSA < 10 were eligible. The COMBO arm was EBRT (45 Gy in 25 fractions) to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results